Optune trials opens for adult patients with low grade gliomas and pediatric patients with high grade gliomas
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
These are exciting trials.
It is nice to see more research on other uses for the Optune device.
Posted on: 10/25/2017
1. Optune trial opens for patients with low grade gliomas
A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
This trial will compare the use of Optune alone against the use of Optune combined with Temodar, in patients with low grade gliomas.
The Temodar will be using a metronomic schedule (daily low dose instead of 5 days of high dose per month) for 1 year. Optune will be used in both arms for 1 year.
2. Optune trial opens for pediatric patients with high grade gliomas! This is a trial of the Optune NovoTTF-200A System With and Without Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Gliomas
Click HERE to return to brain tumor news headlines